The start-up TCHC has obtained funding of 1.2 million dollars for the development of therapies that increase the longevity of cats, based on promising clinical studies.

The Cat Health Company (TCHC), specialized in biotechnology for cats, has secured a funding round of 1.2 million dollars, following an initial funding of 500,000 euros. The investment, led by funds dedicated to longevity, will support the research and development of new therapies. TCHC aims to expand its team and accelerate the approval process of therapies, with the main goal of increasing feline longevity. The company collaborates with international veterinary clinics and aims to obtain regulatory approvals by 2026.